VivoSeq
Oncology

Relapsed/refractory Non-Hodgkin Lymphoma

6

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Relapsed/Refractory Non-Hodgkin Lymphoma is an early-stage landscape with 6 programs across 3 companies. The most active players are Bristol-Myers Squibb, Roche, Genmab.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

PreclinicalRoche logo

Roche

2 programs

PreclinicalGenmab logo

Genmab

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical6

BMS-986458

Bristol-Myers Squibb

Rituximab

Roche

Glofitamab/obinutuzumab

Bristol-Myers Squibb

Mosunetuzumab

Roche

Epcoritamab

Genmab

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Monoclonal antibody

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule233%

Monoclonal antibody leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT06090539·460 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)